ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
ProKidney (Nasdaq: PROK), a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), has announced its participation in the H.C. Wainwright 4th Annual Kidney Virtual Conference. The company's management team will engage in a fireside chat on Monday, July 14, 2025, at 1:30 PM ET.
Investors can access the live webcast through the Events section of ProKidney's Investor Relations webpage at www.prokidney.com. One-on-one meetings are available through H.C. Wainwright representatives.
ProKidney (Nasdaq: PROK), un'azienda terapeutica cellulare in fase clinica avanzata focalizzata sulla malattia renale cronica (CKD), ha annunciato la sua partecipazione al 4° Congresso Virtuale Annuale sul Reni di H.C. Wainwright. Il team di gestione dell'azienda parteciperà a una tavola rotonda informale lunedì 14 luglio 2025, alle 13:30 ET.
Gli investitori potranno seguire la diretta streaming tramite la sezione Eventi della pagina Relazioni con gli Investitori di ProKidney all'indirizzo www.prokidney.com. Sono disponibili incontri individuali tramite i rappresentanti di H.C. Wainwright.
ProKidney (Nasdaq: PROK), una compañía de terapias celulares en etapa clínica avanzada enfocada en la enfermedad renal crónica (ERC), ha anunciado su participación en la 4ª Conferencia Virtual Anual de Riñón de H.C. Wainwright. El equipo directivo de la empresa participará en una charla informal el lunes 14 de julio de 2025 a la 1:30 PM ET.
Los inversores pueden acceder a la transmisión en vivo a través de la sección de Eventos en la página de Relaciones con Inversores de ProKidney en www.prokidney.com. Están disponibles reuniones individuales a través de los representantes de H.C. Wainwright.
ProKidney (나스닥: PROK)는 만성 신장 질환(CKD)에 중점을 둔 후기 임상 단계 세포 치료제 회사로, H.C. Wainwright 제4회 연례 신장 가상 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2025년 7월 14일 월요일 오후 1시 30분(동부시간)에 화상 대화에 참여할 예정입니다.
투자자들은 ProKidney 투자자 관계 웹페이지(www.prokidney.com)의 이벤트 섹션을 통해 생중계 웹캐스트에 접속할 수 있습니다. 1:1 미팅은 H.C. Wainwright 담당자를 통해 예약 가능합니다.
ProKidney (Nasdaq : PROK), une entreprise de thérapies cellulaires en phase clinique avancée axée sur la maladie rénale chronique (MRC), a annoncé sa participation à la 4e Conférence Virtuelle Annuelle sur les Reins de H.C. Wainwright. L'équipe de direction de la société prendra part à une discussion informelle le lundi 14 juillet 2025 à 13h30 ET.
Les investisseurs peuvent accéder à la diffusion en direct via la section Événements de la page Relations Investisseurs de ProKidney sur www.prokidney.com. Des réunions individuelles sont disponibles via les représentants de H.C. Wainwright.
ProKidney (Nasdaq: PROK), ein Unternehmen in der späten klinischen Phase für zelluläre Therapeutika mit Fokus auf chronische Nierenerkrankungen (CKD), hat seine Teilnahme an der 4. jährlichen virtuellen Nierenkonferenz von H.C. Wainwright angekündigt. Das Management-Team des Unternehmens wird am Montag, den 14. Juli 2025, um 13:30 Uhr ET an einem Fireside Chat teilnehmen.
Investoren können das Live-Webcast über den Bereich Veranstaltungen auf der Investor-Relations-Webseite von ProKidney unter www.prokidney.com verfolgen. Einzelgespräche sind über Vertreter von H.C. Wainwright verfügbar.
- None.
- None.
WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference:
| H.C. Wainwright 4th Annual Kidney Virtual Conference | |
| Date: | Monday, July 14, 2025 |
| Time: | 1:30pm ET |
| Format: | Fireside Chat |
| Webcast: | Link |
The live webcast will be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Investors interested in one-on-one meetings should contact their H.C. Wainwright representative.
About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit www.prokidney.com.
Investor Contacts:
ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com
LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com
FAQ
When is ProKidney (PROK) presenting at the H.C. Wainwright Kidney Conference 2025?
How can investors watch ProKidney's (PROK) presentation at the H.C. Wainwright conference?
What is ProKidney's (PROK) main focus as a company?
How can investors arrange one-on-one meetings with ProKidney (PROK) management?
